Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone


Abstract
Elemental diet is as effective as corticosteroids in the treatment of previously untreated Crohn’s disease. It is unclear whether a poor nutritional state is a prerequisite for efficacy of elemental diet, whether previously treated patients respond as well, or how duration of remission using elemental diet compares with corticosteroid induced remission. Forty two patients with active Crohn’s disease were stratified for nutritional state and randomised to receive Vivonex TEN 2·1 l/day for four weeks, or 0·75 mg prednisolone/kg/day for two weeks and subsequent reducing doses. Nine of 22 (41%) patients assigned to nutritional treatment were intolerant of the diet. Thirty patients completed four weeks treatment. Disease activity decreased on elemental diet from mean (SEM) 4·8 (0·9) to 1·7 (0·6), p<0·05, and on prednisolone from 5·3 (0·5) to 1·9 (0·6), p<0·05. For each treatment, nourished and malnourished patients responded similarly. Patients with longstanding disease responded as well as newly diagnosed patients. The probability of maintaining remission at six months was 0·67 after prednisolone, 0·28 after elemental diet, and at one year was 0·35 after prednisolone and 0·09 after elemental diet, p<0·05. When tolerated, elemental diet is as effective in the short term as prednisolone in newly and previously diagnosed Crohn’s disease, and its benefit is independent of nutritional state. The subsequent relapse rate after elemental diet induced remission, however, is greater than after treatment with prednisolone.

(Gut 1993; 34: 1198–1202)

Crohn’s disease is commonly associated with undernutrition, which is often most evident when the disease is active. Nutritional treatment may have a primary therapeutic role in active Crohn’s disease in addition to its proven value as a supportive measure in the overall management of the disease. Chemically defined ‘elemental’ diets containing nutrients in simple, easily assimilable form with nitrogen provided as free amino acids, carbohydrate as simple sugars or glucose polymers, and fat present in very small amounts, were initially used as nutritional support in patients with Crohn’s disease. Subsequently, they have been reported to be as effective as corticosteroids in treating patients with active Crohn’s disease, and one controlled, but non-randomised trial suggested that elemental diet was actually superior to corticosteroid treatment. In childhood Crohn’s disease, attainment of remission using dietary means is particularly attractive, as the growth retarding effects of steroids can be avoided. Elemental diet has been shown to be as beneficial as corticosteroid treatment in children with Crohn’s disease. It is not clear, however, from these published studies whether elemental diet is as efficacious as steroids in previously treated adults with active Crohn’s disease. The only prospective trial directly comparing elemental diet with steroids, which included adult patients who had received treatment for Crohn’s disease in the past, also entailed administration of antibiotics during the 10 day treatment with elemental diet. In addition it is not known whether the influence of nutritional treatment on the disease process is as beneficial in nourished as in undernourished patients. Similarly, the longterm outcome of adult patients treated with elemental diet has not been compared with the outcome after steroid treatment in a prospective fashion. If this treatment changes the fundamental disease process, a prolonged period of remission might be expected in these patients. We have undertaken a randomised trial of elemental diet v prednisolone, to consider these points, in patients with newly diagnosed or recurrent attacks of Crohn’s disease, and followed up the patients for one year after treatment or until relapse.

Methods
Patients with active Crohn’s disease requiring hospital admission were considered for entry into the study. Patients were recruited from three centres, St Bartholomew’s and Central Middlesex Hospitals in London, and Western General Hospital in Edinburgh. The diagnosis of Crohn’s disease was made by colonoscopy with biopsy or characteristic radiological appearances on barium studies. Active Crohn’s disease was defined as at least one of the following: abdominal pain causing severe limitation of activity, diarrhoea (at least 3 loose stools/day), weight loss of more than 2 kg in the past month, or at least two of the following laboratory abnormalities: haemoglobin <12·5 g/dl in men (<10·5 g/dl in women), erythrocyte sedimentation rate >20 mm/h, serum albumin <3·5 g/l.

Patients were excluded if they had evidence of intestinal obstruction, previous gastric surgery, a contraindication to steroid treatment, or had been receiving more than 7·5 mg prednisolone/day at the time of relapse. Patients fulfilling the entry criteria were stratified before randomisation according to whether they were malnourished or not. Patients were considered malnourished if they (a) had lost more than 10% usual body weight or had a serum albumin of

Department of Gastroenterology, St Bartholomew’s Hospital, London D A Gorard J B Hunt M L Clark M J G Farthing

Department of Gastroenterology and Nutrition, Central Middlesex Hospital, London J J Payne-James R G P Rees J J Misiewicz D B A Silk

Gastrointestinal Unit, Western General Hospital, Edinburgh K R Palmer

Correspondence to: Dr D A Gorard, Department of Gastroenterology, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE.

Accepted for publication 21 December 1992
<30 g/l; and (b) also had a triceps skinfold thickness (TSF) of <90% adult reference range or a mid arm muscle circumference (MAMC) <90% reference range.6 Informed consent was obtained from all patients and the study protocol approved by the Research Ethical Committees of the participating centres.

Patients were randomised to receive either prednisolone 0.75 mg/kg body weight daily for two weeks followed by subsequent reducing doses, or elemental diet (Vivonex TEN, Norwich Eaton) as sole treatment for four weeks. The nitrogen source in Vivonex TEN is amino acids comprising 15-3% of its energy value, carboxylate as glucose polymers (maltodextrin), makes up 82-2% of its energy value, and safflower oil contributes just 2-5% of the total energy as fat. Patients receiving elemental diet consumed a minimum of 2.1 litres of standard dilution Vivonex daily, providing 2100 kcal and 12 g nitrogen. This minimum daily intake was reached by day 3, and 'starter regimens' using less than full strength of the feed were not used.9 Those who could not take this minimum daily requirement orally were fed by fine bore nasogastric tube. All other food except water and tea or coffee without milk was prohibited. Patients receiving elemental diet remained in hospital for at least 10 days to ensure compliance. After discharge they were reviewed at weekly intervals and the volume of feed consumed was recorded daily throughout the four week period. After four weeks treatment with elemental diet, normal diet was reintroduced. Patients assigned to receive steroids consumed an unrestricted diet and were asked to record their food intake during the first four weeks. After the first two weeks of prednisolone, the daily dose was steadily reduced to zero over the ensuing weeks. Patients taking sulphasalazine at the time of onset of relapse continued on this drug.

Before treatment was started (week 0), clinical disease severity was assessed using a simple disease activity index (DAI).31 Anthropometric measurements of mid arm circumference (MAC), TSF, MAMC, weight and height were made and expressed as percentage standard MAC, MAMC, TSF, and percentage ideal body weight (%IBW).2 Laboratory measurements of haemoglobin, white cell count, lymphocyte count, erythrocyte sedimentation rate, albumin, urea, and C-reactive protein (CRP) were recorded. These assessments of DAI, anthropometric and laboratory measurements were repeated at week 1, 2, 3, 4, 8, 12, 16, 28, 40, and 52, or sooner if a relapse occurred. A relapse was defined as a clinical deterioration with an increase in DAI requiring (i) high dose steroids, or (ii) surgery. χ² and Wilcoxon rank sum tests were used to compare the characteristics of the two treatment groups at randomisation. The response to treatment was assessed by Wilcoxon signed rank test. Results are expressed as mean (SEM). After treatment, the time to relapse within each treatment group was assessed by lifetable analysis, and the two survival curves obtained were compared using the log rank test.13

### Results

Forty two patients (19 men) were entered into the study. Twenty two patients were randomised to receive prednisolone and 20 to receive elemental diet. Twenty two patients were newly diagnosed and 20 were patients with known Crohn's disease in relapse. Patients within each treatment group were well matched in terms of age, site and duration of disease, nutritional state, initial DAI, laboratory and anthropometric data (Table I).

### Initial Four Weeks Treatment

Of the 22 patients assigned to dietary treatment, nine (41%) could not tolerate elemental diet whether given orally or nasogastrically. The reasons for non-compliance with the diet were its unpalatability and intolerance of a nasogastric tube. These patients were withdrawn from the trial and treated with corticosteroids. Three patients (two on elemental diet, one on prednisolone) deteriorated and required urgent colonic surgery within four weeks of entry. The mean daily intake of Vivonex in those completing four weeks treatment was 2070 ml (2070 kcal). Dietary records of the patients treated with prednisolone were inadequate to make a valid assessment of nutritional intake. For the 30 patients completing four weeks treatment (19 treated with prednisolone, 11 with elemental diet), there were significant improvements in DAI and laboratory indicators of activity. The degree of improvement in both treatment groups was similar (Fig 1). Of the 19 patients completing four weeks prednisolone, 12 had been nourished and seven malnourished at randomisation. Of the 11 patients completing four weeks elemental diet, six were nourished and five malnourished at randomisation.

Despite the overall improvement in both groups, one patient on elemental diet and two on prednisolone achieved only a partial remission at four weeks. In considering these patients, and those requiring early surgery, a failure to achieve complete remission at four weeks was seen in

| TABLE I Comparison of the two treatment groups at randomisation |
|---|---|
| **Prednisolone (n=20)** | **Elemental diet (n=22)** |
| **Age** (mean (SEM))/(yrs) | 32.5 (3.4) | 31.6 (3.0) |
| **Sex** | 16-66 | 16-75 |
| **Disease site** | 7M, 13F | 12M, 10F |
| **Small intestine** | 6 | 7 |
| **Bowel** | 7 | 11 |
| **Colon** | 7 | 4 |
| **Duration** | 11 New, 11 Old (mean duration 9 yrs) | 11 New, 11 Old (mean duration 5 yrs) |
| **Nutritional state** | 12 Nourished, 8 malnourished | 14 Nourished, 8 malnourished |
| **Weight (mean (SEM))/(kg) | 54.8 (3.4) | 54.8 (3.4) |
| **%IBW** | 89.4 (3.8) | 89.4 (3.8) |
| **% Standard MAC** | 85.5 (3.2) | 83.9 (2.8) |
| **% Standard TSF** | 75.2 (3.7) | 77.9 (7.2) |
| **% Standard MAMC** | 90.4 (3.4) | 87.3 (2.9) |
| **Activity index** | 5.1 (0.5) | 5.1 (0.5) |
| **Haemoglobin (g/dl)** | 11.9 (0.48) | 11.8 (0.43) |
| **ESR (mm/h)** | 47.1 (8.2) | 41.3 (7.5) |
| **CRP (mg/l)** | 72.1 (15.8) | 59.7 (11.1) |
| **Albumin (g/l)** | 54.8 (12.6) | 51.6 (9.98) |

1IBW = ideal body weight, MAC = mid arm circumference, TSF = triceps skinfold thickness, MAMC = mid arm muscle circumference, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein.
three of 20 (15%) prednisolone treated patients and three of 13 (23%) patients tolerating elemental diet.

Patients within each treatment arm who were considered malnourished at randomisation responded as well as nourished patients. In the group completing four weeks of elemental diet, there were similar significant (p<0.05) reductions in DAI from 4.6 (0.9) to 2.2 (1.0) in malnourished patients, and from 5.0 (1.6) to 1.3 (0.6) in nourished patients. In those receiving prednisolone, improvements (p<0.05) in DAI, from 4.4 (0.7) to 1.9 (0.6) in malnourished patients, and from 5.8 (0.9) to 1.9 (0.9) in nourished patients, were similar. Patients with a long duration of Crohn’s disease and who had received specific treatment (steroids or surgery) in the past, showed a similar significant (p<0.05) response to elemental diet, DAI decreasing from 6.3 (1.4) to 2.2 (0.8), as newly diagnosed patients, 3.0 (0.6) to 1.2 (0.7). On prednisolone, the DAI improvements (p<0.05) from 5.1 (0.9) to 1.7 (0.6) in previously treated patients, and from 5.6 (0.6) to 2.1 (1.1) in newly diagnosed patients, were also similar.

Serial anthropometric measurements did not improve in those completing four weeks treatment with elemental diet. Within the prednisolone treated group, there was a significant increase in %IBW and percentage standard MAC at four weeks (Table II).

**FOLLOW UP OF REMISSION**

During the 12 months prospective follow up of the 30 patients completing four weeks treatment, one patient (prednisolone treated) was lost to follow up at week 16. After the initial four weeks, patients treated with prednisolone were withdrawn from this drug over a further period of 6-5 (2-4) weeks. During this period, the average daily dosage of prednisolone was 12 (3) mg.

Patients who had relapsed all had a DAI of at least four at the time of relapse. Those patients who had achieved remission on elemental diet relapsed earlier than those who had attained remission on prednisolone (Fig 2). The cumulative probability of maintaining remission at six months was 0.67 after treatment with prednisolone compared with 0.28 after treatment with elemental diet, and at one year the probability of maintaining remission was 0.35 in the prednisolone group and 0.09 in the elemental diet treated group (p<0.05; log rank test). At one year, remission was maintained in only one of the 11 elemental diet treated patients compared with six of the 19 prednisolone treated patients.

Within the elemental diet treated group, five patients with only small intestinal Crohn’s disease tended to relapse later (mean remission period 29 weeks) than six patients who had colonic involvement (mean remission time 13
TABLE II  Anthropometric assessments before and after four weeks treatment with elemental diet or prednisolone

<table>
<thead>
<tr>
<th>Diet</th>
<th>Weight (kg)</th>
<th>%IBW</th>
<th>% Standard</th>
<th>% Standard</th>
<th>% Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elemental diet</td>
<td>wk 0</td>
<td>60.3 (5.6)</td>
<td>91.2 (5.4)</td>
<td>72.3 (6.8)</td>
<td>85.2 (3.2)</td>
</tr>
<tr>
<td></td>
<td>wk 4</td>
<td>59.7 (4.9)</td>
<td>90.6 (4.1)</td>
<td>76.0 (5.7)</td>
<td>82.7 (2.5)</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>wk 0</td>
<td>55.6 (3.5)</td>
<td>90.2 (4.0)</td>
<td>74.9 (7.8)</td>
<td>86.5 (3.2)</td>
</tr>
<tr>
<td></td>
<td>wk 4</td>
<td>57.1 (3.0)</td>
<td>93.1 (3.6)*</td>
<td>80.4 (8.5)</td>
<td>90.4 (2.6)*</td>
</tr>
</tbody>
</table>

*Week 4 result compared with week 0 result p<0.05; abbreviations as in Table I; values expressed as mean (SEM).

weeks), but this difference did not reach statistical significance.

Discussion

This trial has shown that elemental diet, when tolerated, is as effective as prednisolone in treating acute Crohn’s disease in the short term, and confirms the result from the original study of O’Morain et al. In addition, we have shown that elemental diet is as beneficial in patients with longstanding disease as it is in newly diagnosed patients. Unlike previous studies comparing elemental diet with corticosteroids, in this trial we have stratified patients according to nutritional state before randomisation. Our results show that relatively well nourished patients respond equally well to elemental diet as those with a poor nutritional state. A larger number of patients would be necessary, however, to ensure that a small difference in response to elemental diet between nourished and malnourished patients was not being overlooked. Despite the improvements in DAI and laboratory tests, there was no improvement in body weight and anthropometrics in the elemental diet treated patients, whereas the prednisolone treated patients showed increases in %IBW and percentage standard MAC.

Although elemental diet is known to decrease gastrointestinal protein loss, faecal leucocyte excretion, and improve intestinal permeability in acute Crohn’s disease, its underlying mode of action remains unclear. Elemental diet does not exert its beneficial effect by improving nutrition alone, and in this study remission with an elemental diet was achieved as readily in nourished as in malnourished patients.

Polymeric diets containing whole protein are as effective as elemental diets in improving nutrition and are more palatable, but it is unclear whether isocaloric polymeric diets are as successful as elemental diets in inducing remission in acute Crohn’s disease. Furthermore, nutritional treatment with enteral feeds in which nitrogen is provided as a hydrolysate of whole protein has been shown to be inferior to drug treatment in two large studies involving adults, although a small study in children showed equal efficacy to corticosteroids. Preliminary results from the only trial directly comparing polymeric diet with corticosteroids do, however, suggest equal efficacy in inducing remission.

It is widely believed that elemental diet is effective in Crohn’s disease by achieving bowel rest. Its absorption is virtually complete in the proximal small intestine and there is minimal residue, so that the distal small intestine and colon are ‘medically bypassed’. By virtue of its free amino acid content, however, elemental diet provides a powerful stimulus to pancreaticbiliary secretion to which inflamed ulcerated gut is then exposed. Moreover, following a study that failed to show superiority of intravenous nutrition over polymeric feeding or oral food with parenteral supplementation, it is now apparent that complete bowel rest is not essential for achieving remission in acute Crohn’s disease with nutritional treatment.

It has been suggested that in active Crohn’s disease, dietary protein might gain access to the gut wall via ulcerated mucosa and cause secondary immune mediated tissue damage. A unique property of elemental diet, which might account for its effectiveness in acute Crohn’s disease is its hypoallergenic nature. The absence of whole protein or peptides in elemental diet effectively removes dietary antigenic stimuli, which might otherwise provoke immune mediated damage on exposure to ulcerated gut mucosa. This may explain why two trials by the European Co-operative Crohn’s Disease group, both using a protein hydrolysate diet containing oligopeptides rather than solely free amino acids, have shown that enteral feeding is inferior to drug treatment with corticosteroids and sulphasalazine. Another difference in the enteral feeds used in these trials concerns the higher fat content of about 10% total energy, whereas the present and other trials, have used strictly elemental diets containing a very small amount (2-5% of energy) of fat.

Induction of remission using elemental diet avoids the side effects of repeated courses of steroids. In children with Crohn’s disease, elemental diet also improves or reverses growth retardation. Nevertheless, the unpalatability of orally given feed or the inconvenience of nasogastrically given feed, together with the total avoidance of other food requires considerable determination by the patient. Consequently 41% of our patients assigned to dietary treatment, despite hospitalisation, could not tolerate the
elemental diet regimen and we could not reproduce the high compliance rates reported by others. If these non-compliant patients who failed to tolerate four weeks of elemental feeding are taken into account, then just 45% (10 of 22) patients originally randomised to receive four weeks of elemental diet achieved complete remission on diet alone. When compared with 85% (17 of 20) patients achieving remission with prednisolone, elemental diet is inferior (p<0.05) on an intention to treat basis. 

This trial is the first to prospectively follow elemental diet or prednisolone induced remission in adult patients over a period of a year. Some of the patients assigned to prednisolone did receive this drug for more than four weeks. The DAI and laboratory data, however, showed significant improvements at four weeks and continued prednisolone treatment does not protect patients in remission from further relapse. The rate of relapse in elemental diet treated patients was higher than in those who had gained remission with prednisolone. Earlier relapse after elemental diet treatment has also been noted in paediatric patients. We also found that patients with Crohn's disease affecting the colon were likely to relapse more rapidly, a finding that has been noted by others.

In conclusion, this study confirms that four weeks treatment with elemental diet, when tolerated, is as effective as prednisolone. The number of patients intolerant of the diet is disappointingly high and together with inability to sustain a prolonged remission, elemental diet treatment does have its disadvantages. Nevertheless it does have a primary role in managing acute Crohn's disease, and is an attractive alternative to corticosteroids when avoidance of the side effects of corticosteroids is essential.

Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone.

D A Gorard, J B Hunt, J J Payne-James, K R Palmer, R G Rees, M L Clark, M J Farthing, J J Misiewicz and D B Silk

*Gut* 1993 34: 1198-1202
doi: 10.1136/gut.34.9.1198

Updated information and services can be found at:
http://gut.bmj.com/content/34/9/1198

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

Crohn's disease (932)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/